Name of the product: PAMDOSA 30 / 60 / 90

Active ingredient: Disodium Pamidronate 30 mg / 60 mg / 90 mg

Dosage form: lyophilised injection

Dispensing requirements: Rx only

Argentine Industry

Composition:

PAMDOSA 30:

Each glass bottle with lyophilised injection contains disodium pamidronate 30 mg (as disodium pamidronate pentahydrate) and mannitol.

Each glass bottle with dissolving solution contains water for injection.

PAMDOSA 60:

Each glass bottle with lyophilised injection contains disodium pamidronate 60 mg (as disodium pamidronate pentahydrate) and mannitol.

Each glass bottle with dissolving solution contains water for injection.

PAMDOSA 90:

Each glass bottle with lyophilised injection contains disodium pamidronate 90 mg (as disodium pamidronate pentahydrate) and mannitol.

Each glass bottle with dissolving solution contains water for injection.

Indications:

PAMDOSA is indicated for the treatment of bone metabolic diseases like malignant hypercalcemias, osteolytic bone metastases of breast cancer, multiple myeloma or Paget's disease.

Therapeutic action:

Antineoplastic.

Storage:

Keep at temperature below 30º C in the marketed packing.

Marketed presentations:

PAMDOSA 30:

Packs containing 1 glass bottle with lyophilised injection + 1 glass bottle with dissolving solution.

PAMDOSA 60:

Packs containing 1 glass bottle with lyophilised injection + 1 glass bottle with dissolving solution.

PAMDOSA 90:

Packs containing 1 glass bottle with lyophilised injection + 1 glass bottle with dissolving solution.

Medicinal speciality authorised by the Ministry of Health.

Certificate Nº 50841

Laboratorio DOSA S.A.

Girardot 1369, (C1427AKC) Buenos Aires, Argentine

Pharmaceutical Director: María C. Terzo, Pharmacist